SCHEMBL6306130

SCHEMBL6306130

O=S(=O)(N[C@@H]1CCC[C@H]1N1CCC(Cc2ccc(Cl)cc2)CC1)c1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 6/20 0.54
▸ CRHR2 Q13324 6/20 0.54
▸ MCOLN3 Q8TDD5 5/20 0.46
▸ PAX8 Q06710 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ MCOLN2 Q8IZK6 5/20 0.43
▸ MCOLN1 Q9GZU1 5/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ SLC18A3 Q16572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6306126 1.00 CRHBP (0.54) CRHBPCRHR2MCOLN3PAX8KMT2A
SCHEMBL6311367 0.90 CRHBP (0.47) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6311363 0.90 CRHBP (0.47) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6303738 0.88 CRHBP (0.49) CRHBPCRHR2MCOLN3PAX8KMT2A
SCHEMBL6303741 0.88 CRHBP (0.49) CRHBPCRHR2MCOLN3PAX8KMT2A
SCHEMBL6306997 0.87 KMT2A (0.47) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6306994 0.87 KMT2A (0.47) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6306123 0.86 CRHBP (0.46) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6306120 0.86 CRHBP (0.46) CRHBPCRHR2MCOLN3KMT2AMCOLN2
SCHEMBL6306268 0.85 KMT2A (0.47) CRHBPCRHR2MCOLN3KMT2AMCOLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977265-B2 Piperidine CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2005-12-20 — — US disclosed
US-20030229121-A1 Piperidine CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC 2003-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229121-A1 Piperidine CCR-3 receptor antagonists CCR1, CCR3, CCRL2 CRHBP 1470/4885CRHR2 185/4885MCOLN3 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback